Back Bay News and Transaction Updates, March 2024

LATEST HEALTHCARE TRANSACTIONS 

Back Bay's investment banking team advised on four sell-side transactions over the past 90 days. Learn more about the transactions in the company press releases: 

• Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203

• Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203

• Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders

 
Congratulations to the deal teams.

For more information on these transactions or to connect with our team of healthcare advisors at Back Bay and DNB//Back Bay, contact our head of investment banking, Greg Benning or managing director, Vasilios Kofitsas. 

For a look at the latest news from Back Bay Life Science Advisors, check out our newsletter and subscribe here.